TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05288933

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Instrument assisted soft tissue mobilization ( IASTM ) and Ultrasound
Description: Instrument-assisted soft tissue mobilization (IASTM) is a popular treatment for the myofascial limitation that is based on James Cyriax's rationale.~High-power pain threshold ultrasound is a noninvasive approach used in myofascial pain syndrome ( MPS) treatment, and it has no serious adverse effects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Instrument assisted soft tissue mobilization ( IASTM ) and Ultrasound
Description: Instrument-assisted soft tissue mobilization (IASTM) is a popular treatment for the myofascial limitation that is based on James Cyriax's rationale.~High-power pain threshold ultrasound is a noninvasive approach used in myofascial pain syndrome ( MPS) treatment, and it has no serious adverse effects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Instrument assisted soft tissue mobilization ( IASTM ) and Ultrasound
Description: Instrument-assisted soft tissue mobilization (IASTM) is a popular treatment for the myofascial limitation that is based on James Cyriax's rationale.~High-power pain threshold ultrasound is a noninvasive approach used in myofascial pain syndrome ( MPS) treatment, and it has no serious adverse effects.
Study: NCT04736641

Intervention type: OTHER
Intervention: Survey study
Description: Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JOAHDEQ) will be applied
Study: NCT06234527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
Study: NCT05995951

Intervention type: DEVICE
Group type: OTHER
Intervention: Deep Bran Stimulation (DBS)
Description: Deep brain stimulation (DBS) surgery targeting the antero-medial Sub-Thalamic Nucleus (amSTN)

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham-stimulation
Description: Deep brain stimulation (DBS) surgery - Sham stimulation
Study: NCT04798872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based educational program
Description: The mothers and fathers will be provided a website that consist of 6 session. at the end of the session, the lactation consultant will do video call to the mothers to discuss the questions from mothers and fathers. after delivery, telephone counseling will be conducted by lactation consultant to mothers at 2, 4, and 6. weeks postpartum
Study: NCT06525974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: 40mg of Febuxostat once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: 1 g mesalamine three times daily for 3 months.
Study: NCT05805605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplant
Description: On day 0, a target dose of 5 x 106 CD34 cells/kg will be infused.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 MG
Description: 300 mg/day from day -7 to day 0. Allopurinol 150mg/m2/day for pediatric participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 1 hour. Administered on day -6 to day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered as a 2 hour IV infusion on day -6, +3, and +4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Cell Transplant
Description: On day 0, a target dose of 3 x 108 nucleated cells/kg recipient weight will be infused.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: The dose of TBI will be 200 cGy given in a single fraction on day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Pill
Description: All participants begin +5 to day +100.~Loading dose on day +5 of 5 mg/m2/day orally once (max dose of 8 mg).~Maintenance dose 2.5 mg/m2 orally daily to maintain a level of 8-12 ng/ml (max dose of 4 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: All patients begin day +5 through day +35.~3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (maximum of 1 gram per dose) every 8 hours.
Study: NCT04716036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol beverage
Description: Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: placebo beverage condition.
Study: NCT05593237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency rTMS
Description: Stimulation provided at 10 Hz over target brain regions in thirty trains consisting of 10 seconds of stimulation alternating with 50 seconds of rest (3,000 pulses/session)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Frequency rTMS
Description: Stimulation provided at 1 Hz over target brain regions in thirty trains consisting of 10 seconds of stimulation alternating with 50 seconds of rest (300 pulses/session)
Study: NCT04754399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: week 1: 25 mg twice daily, approximately 12 hours apart, with food~week 2: 50 mg twice daily, approximately 12 hours apart, with food~week 3: 75 mg twice daily, approximately 12 hours apart, with food~week 4+: 100 mg twice daily, approximately 12 hours apart, with food
Study: NCT05067894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Protein Subunit Recombinant Vaccine
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Protein Subunit Recombinant Vaccine
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 Inactivated Vaccine
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 Inactivated Vaccine
Description: intramuscular injection
Study: NCT06366438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABC-teen
Description: See above

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentWeb
Description: See above
Study: NCT05911698

Intervention type: DEVICE
Group type: OTHER
Intervention: Fractional co2 laser
Description: The development of fractional resurfacing has led to improvements to melasma treatment with decreased incidence of post-inflammatory hyperpigmentation; these improvements are due to the enhanced healing times and decreased inflammation as a result of the formation of microscopic columns of tissue destruction.~These microscopic columns of damaged tissue are surrounded by areas of normal tissue, allowing for shorter migratory paths for the healing keratinocytes.
Study: NCT04485637

Intervention type: OTHER
Group type: OTHER
Intervention: Communication with basic table
Description: Communication showing only the normal range of blood pressure readings, which is often used but may make it hard to interpret numbers outside of the normal range

Intervention type: OTHER
Group type: OTHER
Intervention: Communication with enhanced table
Description: Communication with enhanced table, with reference information showing how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)

Intervention type: OTHER
Group type: OTHER
Intervention: Communication with enhanced graph
Description: Communication with enhanced graph, showing reference information about how to interpret blood pressure readings (adapted from Blood Pressure UK) with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
Study: NCT05358977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisseel
Description: Intraoperatively, the intervention side will receive topical administration of Tisseel to the blepharoplasty incision. A 2mL syringe of Tisseel product will be used as per the product monograph for an area of \< 8cm2. There will be no variation in surgical counselling or technique, with the exception of the use of Tisseel in one eyelid closure. Both eyelids will otherwise receive standard blepharoplasty surgical techniques. There will be no monitoring of compliance necessary, given the Tisseel will be utilized intraoperatively.
Study: NCT05237739

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical Periodontal treatment (NSPT)
Description: Participants will receive local anesthesia. Thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Treatment chair time will be recorded for each visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Flap Debridement (OFD)
Description: Patients will receive local anesthesia and intrasulcular incisions will be made by buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using piezo-electric/ultrasonic devices with specific thin and delicate tips
Study: NCT06384235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004
Description: LTC004,45μg/kg,IV,Day 1,Q3W;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004
Description: LTC004,45μg/kg,IV,Day 1,Q3W;
Study: NCT04528329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early-Dexamethasone
Description: early use of dexamethasone as early as laboratory evidence of high inflammatory markers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Late dexamethazone
Description: Use of dexamethasone on deterioration of the cases with increased severity
Study: NCT05040919

Intervention type: OTHER
Intervention: collection of medical and socio-demographic data
Description: collection of medical and socio-demographic data

Intervention type: OTHER
Intervention: collection of medical and socio-demographic data
Description: collection of medical and socio-demographic data
Study: NCT05310032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral adminstration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral adminstration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral adminstration
Study: NCT05266651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: oral tablets for one month duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets for one month duration
Study: NCT05245799

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech Language Therapy
Description: Children who are deaf/hard of hearing will receive typical speech and language therapy with a speech pathologist. Reading time is prescribed 20 min, 3x/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Language Therapy
Description: Children who are deaf/hard of hearing will receive typical speech and language therapy with a speech pathologist. Reading time is prescribed 20 min, 3x/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Software Application
Description: The Hear Me Read app is an IOS-based software application that enables parents and speech-language pathologists to partner together to help deaf/hard of hearing children (D/HH) achieve reading, speech and language goals through interactive digital storybook reading.
Study: NCT05239871

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Preoperative transvaginal/transabdominal ultrasonography done according to IDEA criteria.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Preoperative transvaginal/transabdominal ultrasonography done according to IDEA criteria.
Study: NCT04864041

Intervention type: OTHER
Intervention: Evaluation of global longitudinal strain using routinely recorded echocardiography images
Description: There are no particular intervention performed in patients in this study, because echocardiography is part of the standard of care of patients hospitalised in the ICU for vaso occlusive crisis.
Study: NCT04847310

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants in this group will be provided the common primary care treatment by the GP, in a face-to-face consultation that seldom exceeds 10 minutes. TAU usually consists in pharmacological treatment prescribed by the GP, however, it might also consist in practical advice or even non-treatment (Watts et al., 2015). The first consultation will count as part of the recruitment process and, if the patient accepts to participate in the trial, no therapeutic help will be provided to them until they are allocated. Once in the TAU intervention, if the practitioner recommended any psychological treatment as part of it (e.g., referral to specialized care), the participant would be excluded to avoid contamination between clusters. TAU has not a specific amount of sessions; it will finish when the GP considers the patient is recovered.
Study: NCT06075550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single cone technique using TotalFill BC Sealer
Description: Gutta percha cone size X5 (Dentsply, Maillefer) TotalFill BC Sealer (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single cone technique using TotalFill BC Sealer
Description: Gutta percha cone size X5 (Dentsply, Maillefer) TotalFill BC Sealer (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm vertical compaction technique using TotalFill BC Sealer HiFlow
Description: TotalFill BC Sealer HiFlow (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm vertical compaction technique using TotalFill BC Sealer HiFlow
Description: TotalFill BC Sealer HiFlow (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)
Study: NCT06450093

Intervention type: OTHER
Group type: OTHER
Intervention: Preformed stainless steel crown.
Description: A well-fitted preformed stainless-steel crown will be chosen by measuring the mesiodistal dimension of the tooth or its contralateral counterpart, using a graduated periodontal probe for guidance. (6) Tooth preparation will be carried out with #835 diamond fissure bur to reduce occlusal surface up to 1 to 1.5 mm. The interproximal reduction will be made mesially and distally using #169 L tapered diamond bur around 0.5 mm to clear the contact area creating a feather edge finish line. The selected crown size will be checked, and a trial fit will be done before cementation. The crown will be cemented using self-cured RMGI luting cement. The excess will be removed, and proper occlusion will be checked.

Intervention type: OTHER
Group type: OTHER
Intervention: Preformed zirconia crown
Description: The material for crown restoration for this group is the preformed zirconia crown. Tooth preparation will be started by occlusal reduction (1 to 1.5 mm) using #835 diamond fissure bur. The interproximal reduction will be done mesially and distally with #169 L tapered diamond bur in such a way that a straight probe passes freely through the contact area. Rounding of line angles will be done and a knife-edge finish margin of the proximal surface will be obtained avoiding any ledge formation. The selected crown will be placed and checked for a passive fit. Consistent firm finger pressure will be applied during cementation with self-cured RMGI luting cement. Finally, crown placement will be checked.

Intervention type: OTHER
Group type: OTHER
Intervention: Preformed BioFlx crown
Description: The prefabricated BioFlx crown will be used in this group. A similar-sized preformed crown will be selected. Tooth preparation will be carried out similarly to traditional SSCs with #835 diamond fissure bur for occlusal reduction by 1-1.5 mm including the central groove. The proximal preparation will be done mesially and distally with #169 L tapered diamond bur around 0.5 mm to clear the contact area creating a feather edge finish line. Placement of the crown will be achieved by a snug fit. Crown cementation will be carried out using self-cured RMGI luting cement and the excess cement will be removed using a floss or an explorer. (13) Finally, crown placement will be checked
Study: NCT05187559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy
Description: Neuromuscular exercise program with standard physiotherapy with no visual feedback

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex Balance SD and Biodex Gait Trainer
Description: Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
Study: NCT06352125

Intervention type: DIAGNOSTIC_TEST
Intervention: TEG 6s Citrated K, KH, RTH, FFH Cartridge
Description: The TEG® 6s uses the Global Hemostasis with Heparin Neutralization (HN) Cartridge to test the hemostasis properties of citrated blood samples using four different assays/reagents simultaneously, one in each of the four cartridge channels.

Intervention type: DIAGNOSTIC_TEST
Intervention: TEG 6s Citrated K, KH, RTH, FFH Cartridge
Description: The TEG® 6s uses the Global Hemostasis with Heparin Neutralization (HN) Cartridge to test the hemostasis properties of citrated blood samples using four different assays/reagents simultaneously, one in each of the four cartridge channels.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clauss Fibrinogen
Description: Diagnostic Test: Clauss Fibrinogen Fibrinogen, also known as Factor I, is a plasma protein that can be transformed by thrombin into a fibrin gel (the clot). Fibrinogen is synthesized in the liver and circulates in the plasma as a disulfide-bonded dimer of 3 subunit chains. The biological half-life of plasma fibrinogen is 3 to 5 days.
Study: NCT04826276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smoking abstinence
Description: participants will be asked to not smoke for at least 12 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smoking satiety
Description: participants will be asked to smoke as usual
Study: NCT05423483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Home Text Message Reminders
Description: Text messages sent 2x a week with reminders to keep lethal means restricted and surveys of lethal means practices that serve as a prompt to adhere to suggested restriction measures.
Study: NCT05397366

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Task Specific Training
Description: Group A will be given Task Specific protocol with routine physical therapy treatment for 45 mins on the upper limb for 3 days a week for a period of 12 weeks.~This Task Specific protocol will include different exercises like, do the polishing of the table top , can perform arm cradling, can supinate and pronate the cylindrical object with arm , while pushing the cylindrical object can extend the wrist , can reach forward to touch or to pick an object , can bend side ways to pick the object and place it on the table in front , can pour the 1/2cup of water to the wide jar that is held by the patient in other hand , patient can comb his hair , patient can drink and eat independently , can lift the jar and bring it close to lips , can pick up pen by using thumb and two fingers , can do the stacking checkers , can throw a ball into the basket , can push the ball on wall from front and side.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Training
Description: Group B will receive the Neurodevelopmental protocol with the routine physical therapy for 45 mins on the upper limb 3 times a week for period of 12 weeks. The intervention will be performed by the trained physical therapist.~This Neurodevelopmental protocol will include different exercises like , patient should sit while bearing weight , patient can do self-overhead movements with hand clasped , while holding the gymnastic ball reach forward and overhead position while sitting , weight bearing while plantigrade or quadruped position , while sitting or standing can move the ball in forward , backward and sideways.
Study: NCT04820647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KF-STRIDE
Description: KF Stride works to improve identification (awareness) of personal character strengths and 2) express them in a socially appropriate way during a job interview
Study: NCT05931445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-PRO monitoring
Description: The e-PRO monitoring will concern treatment of each predefined type of cancer or characteristic symptoms of the condition. PRO-CTCAE (Patient-Reported Outcome-Common Terminology Criteria for Adverse Events) will be used as the scale for monitoring symptoms. The patient and (sub)investigator will share the monitoring results during examinations and use them to determine treatment strategies, etc. Threshold values will be predefined for a diagnosis of severe for individual symptoms. When it is reported that a threshold value has been exceeded, an alert notification will be sent to the study staff member assigned to the patient. The (sub)investigator who receives the notification will assess the information in the notification and take the best course of action.
Study: NCT05671978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: back-up head elevated position
Description: The patient was then placed in the back-up head elevated position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: neutral position
Description: The patient was then placed in the netural position
Study: NCT05972304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal positive airway System by Vyaire Medical
Description: Incidence of Hypercarbia and Hypoxia in interventional group and its monitoring using transcutaneous (SpO2) and (tCO2) Sensor